VYNE Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

Rhea-AI Summary

VYNE Therapeutics Inc. (Nasdaq: VYNE) will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference, with CEO David Domzalski presenting a pre-recorded fireside chat available on the Company’s website starting November 22, 2021. The chat will commence at 10:00 a.m. Eastern Time. Additionally, VYNE management will hold 1-on-1 meetings with investors during the conference, scheduled from November 29 to December 2.

VYNE aims to develop innovative therapies for immuno-inflammatory conditions and rare skin diseases.

BRIDGEWATER, N.J., Nov. 18, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present at the upcoming Piper Sandler 33^rd Annual Virtual Healthcare Conference.

The presentation will take the form of a pre-recorded fireside chat, which will be available on the Company’s website beginning November 22^nd. Management will also be available for 1-on-1 meetings with investors during the conference November 29^th – December 2^nd.

Presentation details
Date:	Monday, November 22, 2021
Time:	Beginning at 10:00 a.m. Eastern Time
Presentation Type:	Pre-Recorded Fireside Chat

About VYNE Therapeutics Inc.

VYNE’s mission is to improve the lives of patients by developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions. VYNE is working to develop and commercialize a variety of therapies for major immuno-inflammatory conditions and rare skin diseases with high unmet medical need. The Company’s unique and proprietary pipeline includes FMX114 for the potential treatment of mild-to-moderate atopic dermatitis and access to a library of bromodomain & extra-terminal (BET) domain inhibitors in both topical and oral forms for the potential treatment of major immuno-inflammatory conditions and rare skin diseases.

For more information about VYNE Therapeutics Inc. or its investigational products, visit www.vynetherapeutics.com or follow VYNE on Twitter. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.

Investor Relations:
Joseph Ranieri
LifeSci Advisors, LLC
617-430-7582
joer@lifesciadvisors.com

Tyler Zeronda
Chief Financial Officer
VYNE Therapeutics
908-458-9106
Tyler.Zeronda@vynetx.com

FAQ

When is VYNE Therapeutics presenting at the Piper Sandler Virtual Healthcare Conference?

VYNE Therapeutics will present at the Piper Sandler 33rd Annual Virtual Healthcare Conference on November 22, 2021.

What time will the VYNE fireside chat be available?

The fireside chat will be available starting at 10:00 a.m. Eastern Time on November 22, 2021.

Who will represent VYNE Therapeutics at the conference?

David Domzalski, the CEO of VYNE Therapeutics, will present at the conference.

When are the 1-on-1 meetings with VYNE management scheduled?

The 1-on-1 meetings with VYNE management will take place during the conference from November 29 to December 2, 2021.

What is VYNE Therapeutics focusing on in their product development?

VYNE Therapeutics is focused on developing therapies for immuno-inflammatory conditions and rare skin diseases.